SCHEMBL353426

SCHEMBL353426

O=C(NC1=CC(=O)C2OC2C1O)c1cc2nc[nH]c2cc1O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.46
RAB9A P51151 5/20 0.34
MAPT P10636 3/20 0.34
ATM Q13315 2/20 0.34
TP53 P04637 1/20 0.34
NPC1 O15118 4/20 0.33
KMT2A Q03164 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
GAA P10253 1/20 0.33
NAMPT P43490 2/20 0.32
HDAC6 Q9UBN7 1/20 0.32
POLB P06746 4/20 0.31
CASP6 P55212 2/20 0.31
CTDSP1 Q9GZU7 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
HTT P42858 1/20 0.31
F2 P00734 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352080 0.80 PARK7 (0.51) PARK7RAB9AMAPTNPC1KMT2A
SCHEMBL352337 0.80 PARK7 (0.46) PARK7RAB9ANPC1KMT2ASMN1; SMN2
SCHEMBL352091 0.79 PARK7 (0.46) PARK7RAB9ANPC1KMT2ASMN1; SMN2
SCHEMBL665474 0.78 PARK7 (0.49) PARK7RAB9AMAPTNPC1KMT2A
SCHEMBL666087 0.77 PARK7 (0.64) PARK7RAB9AMAPTNPC1KMT2A
SCHEMBL353155 0.74 PARK7 (0.48) PARK7RAB9ANPC1SMN1; SMN2TDP1
Dehydroxymethylepoxyquinomicin SCHEMBL14504317 0.74 PARK7 (0.54) PARK7RAB9AMAPTTP53NPC1
Dehydroxymethylepoxyquinomicin SCHEMBL1669417 0.74 PARK7 (0.54) PARK7RAB9AMAPTTP53NPC1
Dehydroxymethylepoxyquinomicin SCHEMBL1671089 0.74 PARK7 (0.54) PARK7RAB9AMAPTTP53NPC1
Dehydroxymethylepoxyquinomicin SCHEMBL14491796 0.74 PARK7 (0.54) PARK7RAB9AMAPTTP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP claimed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US claimed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US claimed
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
EP-2411376-A1 INHIBITORS OF NF-KB Profectus Biosciences, Inc. (US) 2012-02-01 EP disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed
WO-2010111460-A1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG PARK7 3327/4885RAB9A 2089/4885MAPT 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.